2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1549 Long-term outcomes of a pediatric-inspired chemotherapy regimen with pegaspargase in adults up to age 60 with acute lymphoblastic leukemia: 9-year updated analysis of a phase II trial

Allison J. Li, MD, PhD, Zoe Katsamakis2, Ellen Ritchie, MD3, Shreya Vemuri, BSc, MPH4, Madhulika Shukla5, Martin Tallman, MD6, Dan Douer, MD7, Mark Blaine Geyer, MD8, Jae H Park, MD9
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Weill Cornell Medical College, Hematology and Medical Oncology, Joan and Sanford I. Weill Department of Medicine, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Division of Hematology, Keck School of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Background: Pediatric chemotherapy regimens containing pegaspargase have markedly improved outcomes for adolescents and young adults (AYA) ages 18-39 with acute lymphoblastic leukemia (ALL). However, the optimal strategy to incorporate pediatric regimens in adults ages 40 and older and the upper age limit to balance safety and efficacy have not been established. Therefore, we conducted a phase II, multicenter clinical trial of a pediatric-inspired regimen with strategically sequenced pegaspargase in patients ages 18-60 with newly diagnosed ALL (NCT01920737). Initial results at median 38 months follow-up were previously reported (Geyer et al. Haematologica 2021). Here, we present an updated analysis at 9 years after study completion.

Methods: Eligible adults were 18-60 years of age with newly diagnosed Philadelphia chromosome-negative B- or T-cell ALL/lymphoblastic lymphoma (LBL). The study regimen was adapted from the Children’s Cancer Group 1882 trial augmented arm and consisted of 6 courses of induction, intensification, and re-induction followed by maintenance as previously described. Six doses of pegaspargase 2000 IU/m2 IV were incorporated at ≥4-week intervals to avoid overlapping toxicities with chemotherapy, and 16 doses of intrathecal methotrexate were distributed across the regimen. After a 4-week course of induction 1, all patients received induction 2 regardless of remission status. MRD was assessed by multiparameter flow cytometry with a sensitivity of at least 10-4. Allogeneic hematopoietic cell transplant (alloHCT) in first complete remission (CR1) was decided by the treating physician.

Results: Thirty-nine patients were enrolled and initiated treatment between 2014 to 2017. Median age was 38 years (range 20-60) with 54% ages 18-39 (AYA) and 46% ages 40-60 (older), 23% female, 5% Hispanic, 8% Asian, and 79% White. Baseline disease features included 69% B-ALL/LBL (older: 67%), 31% T-ALL/LBL (older: 33%), 8% CNS involvement (older: 0%), and 41% other extramedullary involvement (older: 39%). Among AYA patients, 21/21 (100%) achieved CR or CR with incomplete hematologic recovery (CRi) by the end of induction 2 with 11/13 (85%) MRD-negative. Among older patients, 17/18 (94%) achieved CR/CRi after induction 2 with 9/11 (82%) MRD-negative. Five AYA and 5 older patients (26%) received alloHCT after achieving CR1 on study (due to MRD after induction 2, n=3; unfavorable genetics, n=3; physician preference, n=4).

Grade 3-4 pegaspargase-associated adverse events (AE) were: 59% hypofibrinogenemia, 59% hypertriglyceridemia, 41% transaminitis, 31% hyperglycemia, 26% hyperbilirubinemia, 3% pancreatitis, and 3% thrombosis. As previously reported, hyperbilirubinemia was the only grade 3-4 AE more common in older compared with AYA patients (44% vs 10%; p=0.025), but 8/10 patients resumed pegaspargase per protocol dosing without recurrence. Overall, 62% of AYA and 44% of older patients received at least 3 doses of pegaspargase.

We previously reported morphologic relapses in 4 AYA and 6 older patients at median 15.4 months (range 5.4-50.4) after treatment initiation. We now report that with extended median follow-up of 122 months (95% confidence interval [CI] 112-138) available for 22 patients (10/22 older patients) treated at our center, there were no new relapses and 7/22 patients (3/7 older patients) were in sustained remission without receiving alloHCT in CR1. Notable long-term follow-up events included head and neck squamous cell carcinoma in one patient at 6.5 years and death of one patient due to acute myeloid leukemia (presumed therapy-related) at 4 years. The estimated 10-year OS was 73% (95% CI 49-87) and EFS was 68% (95% CI 45-83); differences in overall OS (p=0.27) and EFS (p=0.58) were not statistically significant between AYA and older patients.

Conclusions: This pediatric-inspired chemotherapy regimen for Ph- ALL with 6 doses of rationally sequenced pegaspargase resulted in high rates of MRD-negative CR with durable long-term EFS and OS for both AYA and patients aged 40-60 and with no late relapses. Although pegaspargase-associated AEs were common, most patients did not require treatment discontinuation and toxicities were transient and manageable. These findings indicate that our pediatric-inspired regimen can be safely given to adults up to age 60 and can serve as a backbone incorporating blinatumomab consolidation for B-ALL as well as new agents to optimize treatment efficacy and tolerability in older adults.

Allison J. Li, MD, PhD: No relevant conflicts of interest to declare.